<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00107185</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000420930</org_study_id>
    <secondary_id>UCLA-0410044-01</secondary_id>
    <nct_id>NCT00107185</nct_id>
  </id_info>
  <brief_title>Vaccine Therapy in Treating Young Patients Who Are Undergoing Surgery for Malignant Glioma</brief_title>
  <official_title>Phase I Dose Escalation Study of Autologous Tumor Lysate-Pulsed Dendritic Cell Immunotherapy for Malignant Gliomas in Pediatric Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jonsson Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jonsson Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Vaccines made from a person's white blood cells and tumor cells may help the body&#xD;
      build an effective immune response to kill tumor cells. Giving vaccine therapy after surgery&#xD;
      may be a more effective treatment for malignant glioma.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of vaccine therapy in&#xD;
      treating young patients who are undergoing surgery for malignant glioma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the dose-limiting toxicity of adjuvant vaccination with autologous tumor&#xD;
           lysate-pulsed dendritic cells after surgical resection in pediatric patients with&#xD;
           malignant glioma.&#xD;
&#xD;
        -  Determine the maximum tolerated dose of this vaccine in these patients.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine, preliminarily, the survival of patients treated with this vaccine.&#xD;
&#xD;
        -  Determine, preliminarily, the time to tumor progression in patients treated with this&#xD;
           vaccine.&#xD;
&#xD;
        -  Determine cellular immune response in patients treated with this vaccine.&#xD;
&#xD;
        -  Determine age-dependent differences in response to this vaccine, in terms of&#xD;
           immunocompetence, in these patients.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study.&#xD;
&#xD;
      Patients undergo surgical resection to obtain tumor tissue for production of tumor lysate.&#xD;
      Patients then undergo leukapheresis to obtain peripheral blood mononuclear cells (PBMC) for&#xD;
      generation of dendritic cells (DC). DC are pulsed with tumor lysate to produce an autologous&#xD;
      dendritic cell vaccine. Approximately 10-30 days after leukapheresis, patients receive&#xD;
      vaccination with autologous tumor lysate-pulsed dendritic cells intradermally on days 0, 14,&#xD;
      and 28 in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of vaccine until the maximum tolerated dose&#xD;
      (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6&#xD;
      patients experience dose-limiting toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed at 2 weeks and then every 2 months&#xD;
      for 1 year.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 3-18 patients will be accrued for this study within 2-4.5&#xD;
      years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2005</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose-limiting toxicity of adjuvant vaccination with autologous tumor lysate-pulsed dendritic cells after surgical resection in pediatric patients with malignant glioma.</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>survival</measure>
    <time_frame>1 year</time_frame>
    <description>survival with this vaccine</description>
  </secondary_outcome>
  <other_outcome>
    <measure>time to progression</measure>
    <time_frame>1 year</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Brain and Central Nervous System Tumors</condition>
  <arm_group>
    <arm_group_label>Vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>therapeutic autologous dendritic cells</intervention_name>
    <arm_group_label>Vaccine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed* WHO grade III or IV malignant glioma of 1 of the following&#xD;
             subtypes:&#xD;
&#xD;
          -  Anaplastic astrocytoma&#xD;
&#xD;
          -  Anaplastic oligodendroglioma&#xD;
&#xD;
          -  Glioblastoma multiforme NOTE: *Must be confirmed after surgery&#xD;
&#xD;
          -  Newly diagnosed OR recurrent disease&#xD;
&#xD;
          -  Bidimensionally measurable disease by contrast-enhancing pre-operative MRI&#xD;
&#xD;
          -  Surgically accessible tumor for which surgical resection is indicated at the time of&#xD;
             initial pre-operative evaluation&#xD;
&#xD;
          -  Must have undergone standard surgery* AND either radiotherapy* or chemoradiotherapy*&#xD;
&#xD;
          -  Objective evidence of disease by contrast-enhanced brain MRI after completion of&#xD;
             standard therapy NOTE: *Completed after study entry but before assignment to study&#xD;
             treatment cohorts&#xD;
&#xD;
          -  Age 1 to 18&#xD;
&#xD;
          -  Performance status Karnofsky 60-100%&#xD;
&#xD;
          -  Hematopoietic&#xD;
&#xD;
               -  Hemoglobin ≥ 10 g/dL&#xD;
&#xD;
               -  Absolute granulocyte count ≥ 1,500/mm^3&#xD;
&#xD;
               -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  Hepatic&#xD;
&#xD;
               -  SGPT and SGOT ≤ 2 times normal&#xD;
&#xD;
               -  Alkaline phosphatase ≤ 2 times normal&#xD;
&#xD;
               -  Bilirubin ≤ 1.5 mg/dL&#xD;
&#xD;
               -  Hepatitis B and C negative&#xD;
&#xD;
          -  Renal&#xD;
&#xD;
               -  BUN ≤ 1.5 times normal OR&#xD;
&#xD;
               -  Creatinine ≤ 1.5 times normal&#xD;
&#xD;
          -  Immunologic&#xD;
&#xD;
               -  HIV negative&#xD;
&#xD;
               -  Syphilis negative&#xD;
&#xD;
          -  At least 2 weeks since prior radiotherapy and recovered&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas) and recovered&#xD;
&#xD;
          -  No chemotherapy during and for 4 weeks* after the final dose of study vaccine&#xD;
&#xD;
          -  No corticosteroids for at least 10 days before leukapheresis&#xD;
&#xD;
          -  No concurrent corticosteroids&#xD;
&#xD;
          -  More than 72 hours since prior systemic antibiotics&#xD;
&#xD;
          -  No antihistamines for 5 days before and for 5 days after administration of study&#xD;
             vaccine&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  history of immunodeficiency or autoimmune disease that may be exacerbated by&#xD;
             immunotherapy, including any of the following:&#xD;
&#xD;
          -  Rheumatoid arthritis&#xD;
&#xD;
          -  Systemic lupus erythematosus&#xD;
&#xD;
          -  Vasculitis&#xD;
&#xD;
          -  Polymyositis&#xD;
&#xD;
          -  Dermatomyositis&#xD;
&#xD;
          -  Scleroderma&#xD;
&#xD;
          -  Multiple sclerosis&#xD;
&#xD;
          -  Juvenile-onset insulin-dependent diabetes&#xD;
&#xD;
          -  active infection&#xD;
&#xD;
          -  fever&#xD;
&#xD;
          -  allergy to study reagents&#xD;
&#xD;
          -  pregnant or nursing&#xD;
&#xD;
          -  other malignancy within the past 5 years except adequately treated basal cell or&#xD;
             squamous cell skin cancer, localized prostate cancer, or carcinoma in situ of the&#xD;
             cervix&#xD;
&#xD;
          -  unstable or severe medical or psychiatric condition, as determined by the investigator&#xD;
&#xD;
          -  underlying condition that would preclude study participation&#xD;
&#xD;
          -  concurrent radiotherapy&#xD;
&#xD;
          -  prior organ allograft&#xD;
&#xD;
          -  concurrent strong painkillers&#xD;
&#xD;
          -  other concurrent immune-suppressing medications&#xD;
&#xD;
          -  other concurrent investigational agents&#xD;
&#xD;
          -  other adjuvant treatment for 4 weeks* after the final dose of study vaccine NOTE:&#xD;
             *Unless there is evidence of tumor progression necessitating additional&#xD;
             clinically-indicated treatment; patients requiring treatment due to tumor progression&#xD;
             are removed from the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph L. Lasky, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jonsson Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jonsson Comprehensive Cancer Center at UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-1781</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <study_first_submitted>April 5, 2005</study_first_submitted>
  <study_first_submitted_qc>April 5, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 6, 2005</study_first_posted>
  <last_update_submitted>August 3, 2020</last_update_submitted>
  <last_update_submitted_qc>August 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>childhood high-grade cerebral astrocytoma</keyword>
  <keyword>recurrent childhood cerebral astrocytoma</keyword>
  <keyword>childhood oligodendroglioma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioma</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

